AR099312A1 - Derivados de nucleósidos sustituidos con 4-difluorometil como inhibidores de la replicación del arn de influenza - Google Patents

Derivados de nucleósidos sustituidos con 4-difluorometil como inhibidores de la replicación del arn de influenza

Info

Publication number
AR099312A1
AR099312A1 ARP150100356A ARP150100356A AR099312A1 AR 099312 A1 AR099312 A1 AR 099312A1 AR P150100356 A ARP150100356 A AR P150100356A AR P150100356 A ARP150100356 A AR P150100356A AR 099312 A1 AR099312 A1 AR 099312A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
independently
phenyl
together form
aryl
Prior art date
Application number
ARP150100356A
Other languages
English (en)
Inventor
Smith Mark
G Klumpp Klaus
Original Assignee
Riboscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riboscience Llc filed Critical Riboscience Llc
Publication of AR099312A1 publication Critical patent/AR099312A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La solicitud divulga derivados de nucleósidos como inhibidores de la replicación del ARN de influenza. En particular, la solicitud divulga el uso de derivados de nucleósidos purínicos y pirimidínicos como inhibidores de replicación del ARN de influenza y composiciones farmacéuticas que contienen tales compuestos. Reivindicación 1: Un compuesto inhibidor de la replicación del ARN de influenza de fórmula (1) caracterizado porque: Y es H o P(=X)(R)(R); R es O-R¹ o NHR¹; R¹ es -C(R²ᵃ)(R²ᵇ)C(=O)OR³; R es N(R⁴)C(R²ᵃ)(R²ᵇ)C(=O)OR³, -OP(=O)(OH)OP(=O)(OH)OH, o -OR³; R¹ es H, haloalquilo inferior, o arilo, en donde el arilo es fenilo o naftilenilo, opcionalmente sustituido con uno o más de alquilo inferior, alquenilo inferior, alquinilo inferior, alcoxi inferior, halo, haloalquilo inferior, -N(R¹ᵃ)₂, acilamino, -SO₂N(R¹ᵃ)₂, -C(=O)R¹ᵇ, -SO₂(R¹ᶜ), -NHSO₂(R¹ᶜ), nitro, ciano, o R¹; cada R¹ᵃ es independientemente H o alquilo inferior; cada R¹ᵇ es independientemente -OR¹ᵃ o -N(R¹ᵃ)₂; cada R¹ᶜ es alquilo inferior; cada R²ᵃ y R²ᵇ es independientemente H, alquilo inferior, (CH₂)ʳN(R¹ᵃ)₂, hidroxialquilo inferior, -CH₂SH, -(CH₂)S(O)ₚMe, -(CH₂)ₙNHC(=NH)NH₂, (1H-indol-3-il)metilo, (1H-indol-4-il)metilo, -(CH₂)ₘC(=O)R¹ᵇ, arilo y arilalquilo inferior, en donde el arilo está opcionalmente sustituido con uno o más de hidroxi, alquilo inferior, alcoxi inferior, halo, nitro o ciano; m es 0, 1, ó 2; n es 1, 2, ó 3; p es 1 ó 2; r es 1 ó 2; o R²ᵃ es H y R²ᵇ y R⁴ juntos forman (CH₂)ₙ; cada R³ es independientemente H, alquilo inferior, haloalquilo inferior, fenilo o fenil-alquilo inferior, en donde el fenilo y el fenil-alquilo inferior están opcionalmente sustituidos con alcoxi inferior; o R³ y R¹ juntos forman CH₂; cada R⁴ es independientemente H, alquilo inferior; o R²ᵇ y R⁴ juntos forman (CH₂)₃; Rʷ, Rʸ, y Rᶻ son cada uno independientemente H, OH o F; Rˣ es H, OH, o F; o R³ y Rˣ juntos forman una unión; o R¹ y Rˣ juntos forman una unión; X es O ó S; la Base es uracilo, citosina, guanina, adenina, timina, o heterocicloalquilo, cada uno de los cuales puede estar opcionalmente sustituido con uno o más de hidroxi, alquilo inferior, alcoxi inferior, halo, nitro o ciano; con la condición de que si Rʷ es H, Rʸ es H, y Rᶻ es H, entonces Rˣ no es H; y con la condición de que la fórmula (1) no es ((2R,3R,4R,5R)-5-(4-amino-2-oxopirimidin-1(2H)-il)-2-(difluorometil)-4-fluoro-3-hidroxitetrahidrofuran-2-il)metil tetrahidrógeno trifosfato; o una sal farmacológicamente aceptable del mismo.
ARP150100356A 2014-02-06 2015-02-06 Derivados de nucleósidos sustituidos con 4-difluorometil como inhibidores de la replicación del arn de influenza AR099312A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461936569P 2014-02-06 2014-02-06

Publications (1)

Publication Number Publication Date
AR099312A1 true AR099312A1 (es) 2016-07-13

Family

ID=53774368

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100356A AR099312A1 (es) 2014-02-06 2015-02-06 Derivados de nucleósidos sustituidos con 4-difluorometil como inhibidores de la replicación del arn de influenza

Country Status (20)

Country Link
US (2) US9370569B2 (es)
EP (1) EP3102215B1 (es)
JP (1) JP6581100B2 (es)
KR (1) KR102327464B1 (es)
CN (1) CN105979951B (es)
AR (1) AR099312A1 (es)
AU (1) AU2015213791B2 (es)
CA (1) CA2945693C (es)
CL (1) CL2016001973A1 (es)
CR (1) CR20160400A (es)
EA (1) EA033866B1 (es)
HK (1) HK1225617A1 (es)
IL (1) IL246929B (es)
MA (1) MA39317A1 (es)
MX (1) MX2016010105A (es)
PE (1) PE20170203A1 (es)
PH (1) PH12016501567A1 (es)
SG (1) SG11201606368WA (es)
TW (1) TWI620755B (es)
WO (1) WO2015120237A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA122121C2 (uk) 2014-02-06 2020-09-25 Хептерс Терап'Ютікс Лімітед Біциклічні азотовмісні сполуки як агоністи мускаринового м1 рецептора i/або м4 рецептора
EA033866B1 (ru) * 2014-02-06 2019-12-03 Рибосайенс Ллк 4'-дифторметилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гриппа
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
CN112156102B (zh) * 2015-09-16 2023-10-03 济南高合医疗科技有限公司 一种nuc-1031单一异构体的晶型及其制备方法
CN106543220A (zh) 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
WO2019027905A1 (en) * 2017-07-31 2019-02-07 January Therapeutics, Inc. ORGANOPHOSPHATE DERIVATIVES
CN111434671B (zh) * 2019-01-11 2023-07-11 凯思凯迪（上海）医药科技有限公司 肝脏特异性ampk激动剂及其制法和应用
US11198699B2 (en) * 2019-04-02 2021-12-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5
WO2020223530A1 (en) * 2019-04-30 2020-11-05 Cure Biopharma Inc. Gemcitabine prodrugs
JP2022532520A (ja) * 2019-05-03 2022-07-15 ターンズ・ファーマシューティカルズ・インコーポレイテッド 癌を処置するための化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
WO2022221514A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
WO2022266384A1 (en) * 2021-06-17 2022-12-22 Terns Pharmaceuticals, Inc. Methods for treating cancer
WO2023178133A1 (en) * 2022-03-15 2023-09-21 Rome Therapeutics, Inc. Compounds and methods for treating disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192749A (en) * 1990-05-21 1993-03-09 Syntex (U.S.A.) Inc. 4'-substituted nucleosides
BR0114837A (pt) * 2000-10-18 2006-05-09 Pharmasset Ltd nucleosìdeos modificados para tratamento de infecções viróticas e proliferação celular anormal
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
US20040229840A1 (en) 2002-10-29 2004-11-18 Balkrishen Bhat Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
CA2812962C (en) 2010-09-22 2020-03-31 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
SG10201610936RA (en) 2011-12-22 2017-02-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
EP3351552B1 (en) * 2012-03-13 2021-05-19 Gilead Sciences, Inc. 2'-substituted carba-nucleoside analogs for antiviral treatment
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN104203253A (zh) * 2012-03-21 2014-12-10 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
AU2013266393B2 (en) 2012-05-22 2017-09-28 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
EP3421482A1 (en) 2012-12-21 2019-01-02 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
TW201542578A (zh) 2013-06-26 2015-11-16 Alios Biopharma Inc 經取代之核苷、核苷酸及其類似物
TW201524990A (zh) 2013-10-11 2015-07-01 Alios Biopharma Inc 經取代之核苷、核苷酸及其類似物
EA033866B1 (ru) * 2014-02-06 2019-12-03 Рибосайенс Ллк 4'-дифторметилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гриппа

Also Published As

Publication number Publication date
SG11201606368WA (en) 2016-09-29
EA033866B1 (ru) 2019-12-03
WO2015120237A2 (en) 2015-08-13
AU2015213791A1 (en) 2016-09-08
AU2015213791B2 (en) 2019-11-14
TWI620755B (zh) 2018-04-11
CR20160400A (es) 2016-11-07
PH12016501567A1 (en) 2016-09-14
EP3102215A2 (en) 2016-12-14
WO2015120237A3 (en) 2015-11-05
JP2017506229A (ja) 2017-03-02
TW201538517A (zh) 2015-10-16
EP3102215A4 (en) 2018-01-24
EP3102215B1 (en) 2021-06-16
US20170296664A1 (en) 2017-10-19
MX2016010105A (es) 2016-11-15
IL246929A0 (en) 2016-09-29
NZ723551A (en) 2020-09-25
KR102327464B1 (ko) 2021-11-16
EA201691554A1 (ru) 2016-12-30
JP6581100B2 (ja) 2019-09-25
IL246929B (en) 2019-09-26
US10092649B2 (en) 2018-10-09
CN105979951A (zh) 2016-09-28
PE20170203A1 (es) 2017-03-16
CL2016001973A1 (es) 2017-02-17
US20150225441A1 (en) 2015-08-13
CN105979951B (zh) 2020-12-25
HK1225617A1 (zh) 2017-09-15
MA39317A1 (fr) 2018-01-31
US9370569B2 (en) 2016-06-21
CA2945693C (en) 2020-06-16
CA2945693A1 (en) 2015-08-13
KR20160145542A (ko) 2016-12-20

Similar Documents

Publication Publication Date Title
AR099312A1 (es) Derivados de nucleósidos sustituidos con 4-difluorometil como inhibidores de la replicación del arn de influenza
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
PE20161443A1 (es) Compuestos
GEP201706793B (en) Substituted nucleosides, nucleotides and analogs thereof
CR20190156A (es) Derivados de bipirazol como inhibidores jak
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
PE20160869A1 (es) Derivados novedosos de amino pirimidina
MA38347A1 (fr) Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'inhibiteurs de janus kinases (jak)
GT201400301A (es) 7h-pirrolo [2,3-d] pirimidinas-4- ( aminho-substituidas) novedosas como inhibidores de lrrk2
PE20050462A1 (es) COMPUESTOS DE 5,7-DIAMINOPIRAZOLO[4,3-d]PIRIMIDINAS COMO INHIBIDORES DE LA FOSFODIESTERASA TIPO 5 (PDE-5)
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
AR096235A1 (es) Arilquinazolinas
SG195319A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
MA40219A (fr) Sels cristallins de (s)-6-((1-acétylpipéridin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
AR054559A1 (es) Derivados de purina como inhibidores del receptor a2a de adenosina
NI201000231A (es) Inhibidores de ciclopropil polimerasa.
MX2015015786A (es) Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il) arilcarboxamida sustituidos y su uso como herbicidas.
NZ629037A (en) Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
TW200626605A (en) Novel bis-azaindole derivatives, their preparation and their pharmaceutical use as kinase inhibitors
CU20170123A7 (es) Heterociclilmetil-tienouracilo como antagonistas del receptor de adenosina-a2b
AR110753A1 (es) Inhibidores selectivos de jak1
IN2014DN10239A (es)
IN2015DN00538A (es)
HN2011003482A (es) Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb)

Legal Events

Date Code Title Description
FB Suspension of granting procedure